The patent of IMM0306 of ImmuneOnco was authorized by China Intellectual Property Office
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the IMM0306 project of the company has recently obtained the invention patent authorization of the China Intellectual Property Office (China patent application No.: CN201710151979.6). Meanwhile, the IMM0306 project has applied for invention patents in the United States, the European Union, Japan and other countries and regions.
"The IMM0306 project first obtained the invention patent authorization in China, which will greatly improve the market competitiveness of the project. This is the second Chinese invention patent authorization related to CD47 target obtained by ImmuneOnco after IMM01 (SIRPa-Fc), and it is also the seventh invention patent authorization accumulated worldwide, which fully reflects the strong R & D and innovation ability of the company's R & D team. " "IMM0306 is an antibody receptor recombinant protein (mAb-Trap) that simultaneously targets CD47 and CD20, and is the first CD47xCD20 double target specific molecule in the world to enter the clinical trial stage," said Tian Wenzhi, founder and chairman of ImmuneOnco. IMM0306 does not combine with human red blood cells. Clinical trials are progressing as planned. We are looking forward to the clinical manifestations of IMM0306. "
IMM0306 is an antibody receptor recombinant protein (mAb-Trap) targeting CD47 and CD20 at the same time. It is the world's first (First-In-Class) bispecific antibody drug with independent intellectual property rights of ImmuneOnco. The drug can act on tumor disease targets and regulate immune system at the same time, and play a strong anti-tumor effect by activating macrophages and NK cells.
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded in June 2015 and registered in Zhangjiang High Tech Park, Shanghai. The company is mainly committed to the development and research of tumor immunotherapy products, including bispecific antibodies, new recombinant proteins, and TNAKTM cell therapy. The company's first product, IMM01, and its second product, IMM0306, are in phase I clinical trial study. Several other double target specific protein drugs are in preclinical research stage.
Address: Room 502, 1043 HaLei Road, Pudong New Area, Shanghai, China
Building 7, Lane 908, Ziping Road, Pudong New Area, Shanghai, China
Tel. + 86 21 5835 6573